New findings bring hope to Vancouver AIDS conference.
D016915:AIDS Vaccines; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003906:Developing Countries; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D016915:AIDS Vaccines; D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir